FDA promis­es Roche a snap de­ci­sion on Tecen­triq triple for front­line lung can­cer as it falls even fur­ther be­hind Mer­ck, Bris­tol-My­ers

Roche is get­ting some help from the FDA in its quest to start mak­ing up some of the multi­bil­lion-dol­lar dis­tance that sep­a­rates the glob­al play­er from Mer­ck and Bris­tol-My­ers Squibb in the block­buster ri­val­ry over the lung can­cer mar­ket. The agency is hand­ing Roche and its big can­cer di­vi­sion Genen­tech a pri­or­i­ty re­view for a triple us­ing its PD-L1 check­point Tecen­triq plus Avastin and chemo in front­line lung can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER